Skip to main content
HCPCS Level II/M-Codes/M1408

M1408 HCPCS Level II Code: Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer

M1408 is the authoritative medical code for Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer. This classification is used in medical billing and clinical recording to specify the clinical criteria for patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer (HCPCS Level II M1408), ensuring healthcare documentation aligns with current federal coding standards.

Billing Status: Processed within HCPCS Level II standards. CMS regulatory guidelines apply.

Medicare Coverage & Payment

  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Service not separately priced (pricing indicator 00)
  • BETOS: Z2
  • Effective: January 1, 2025

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Official Registry Overview & Definition

Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer is a HCPCS Level II code (M1408) for a Medicare-covered supply, service, or procedure. Short description: Gmln brca bef dx ca.

Nearest Codes in This Family

Official HCPCS Level II classifications closest to M1408 in its code family, with their registry titles.

  • M1403 — Patients with baseline and follow-up promis surveys documented in the medical record
  • M1404 — Patients on a therapeutic clinical trial
  • M1405 — Patients with recurrence/disease progression
  • M1406 — Patients who leave the practice during the follow-up period
  • M1407 — Patients who died during the follow-up period
  • M1409 — Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
  • M1410 — Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
  • M1411 — Currently on first-line immune checkpoint inhibitors without chemotherapy
  • M1412 — Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
  • M1413 — Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy